MedTrace Logo

sFlt1: a Biomarker of Organ Dysfunction in Critically-ill Patients With COVID-19?

NCT04394195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 72

Last updated 2021-04-01

No results posted yet for this study

Summary

Short description of the protocol intended for the lay public. Include a brief statement of the study hypothesis (Limit : 5000 characters) The management of critically-ill patients with organ failure due to COVID-19 represents a major healthcare burden. While endothelial inflammation has been reported in these patients, the pathophysiological mechanisms remain incompletely elucidated.

Conditions

  • CORONAVIRUS INFECTIONS

Interventions

OTHER

measurement of circulating sFlt1 concentration

blood circulating sFlt1 concentration will be determined

Sponsors & Collaborators

  • CHU de Reims

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-03
Primary Completion
2020-05-01
Completion
2020-09-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04394195 on ClinicalTrials.gov